<DOC>
	<DOCNO>NCT00404495</DOCNO>
	<brief_summary>This study ass rate objective confirm tumor response irinotecan combination temozolomide child recurrent refractory medulloblastoma child newly diagnose high-grade glioma .</brief_summary>
	<brief_title>Combination Irinotecan Temozolomide Children With Brain Tumors .</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Cohort 1 : Recurrent refractory medulloblastoma current standard treatment approach fail ; biopsy require recurrent disease . Cohort 2 : Newlydiagnosed highgrade glioma ( World Health Organization [ WHO ] grade 3 4 ) Life expectancy â‰¥ 3 month Diagnosis brainstem glioma Concurrent administration antitumor therapy Preexisting uncontrolled diarrhea</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>